Overview Dividends

(JAZZ) Jazz Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00B4Q5ZN47

Xywav, Xyrem, Epidiolex, Rylaze, Vyxeos

JAZZ EPS (Earnings per Share)

EPS Growth (3Y CAGR): 27.38%
EPS Trend (3Y Correlation): -23.6%

JAZZ Revenue

Revenue Growth (3Y CAGR): 5.49%
Revenue Trend (3Y Correlation): 56.0%

Risk via 10d forecast
Volatility	30.2%
Value at Risk 5%th	47.1%
Relative Tail Risk	-5.29%

Reward TTM
Sharpe Ratio	0.35
Alpha	-0.40

Character TTM
Hurst Exponent	0.441
Beta	0.817
Beta Downside	1.160

Drawdowns 3y
Max DD	39.07%
Mean DD	21.82%
Median DD	22.94%

Description: JAZZ Jazz Pharmaceuticals November 06, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a Dublin-based specialty biopharma that develops and commercializes products across neurology, oncology, and hematology in the U.S., Europe, and other markets. Its approved portfolio includes Xywav and Xyrem for narcolepsy-related sleep disorders, Epidiolex for rare epilepsies, Rylaze/Enrylaze for acute lymphoblastic leukemia/lymphoblastic lymphoma, Zepzelca for small-cell lung cancer, Ziihera for HER-2 positive biliary tract cancers, Defitelio for veno-occlusive disease, and Vyxeos for therapy-related acute myeloid leukemia. The pipeline features late-stage assets such as Zanidatamab (Phase 3 HER-2 GEA), Suvecaltamide (Phase 2 Parkinson’s tremor), and several early-stage candidates targeting RAF kinase, interferon-alpha, and sleep disorders.

Key quantitative points (FY 2023): revenue of approximately $2.5 billion, with >55 % derived from specialty CNS and oncology products; R&D intensity around 15 % of sales, reflecting a focus on high-margin, niche indications; and a cash-and-equivalents position of roughly $1.2 billion, providing runway for upcoming trial readouts. Macro-level drivers include an aging population that expands demand for sleep-disorder therapies, continued growth in the global oncology market (projected CAGR ≈ 6 % through 2030), and favorable reimbursement trends for specialty drugs in the U.S.

For a deeper quantitative assessment, the ValueRay platform provides a granular breakdown of Jazz’s valuation metrics and scenario analysis.

JAZZ Stock Overview

Market Cap in USD	7,970m
Sub-Industry	Pharmaceuticals
IPO / Inception	2007-06-01
Return 12m vs S&P 500	-2.54%
Analyst Rating	4.44 of 5

JAZZ Dividends

Currently no dividends paid

JAZZ Growth Ratios

CAGR 3y	-0.80%
CAGR/Max DD Calmar Ratio	-0.02
CAGR/Mean DD Pain Ratio	-0.04
Current Volume	859.1k
Average Volume	626.9k

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (-368.5m TTM) > 0 and > 6% of Revenue (6% = 249.5m TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA 2.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 35.64% (prev 84.16%; Δ -48.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 1.39b > Net Income -368.5m (YES >=105%, WARN >=100%)

Net Debt (-243.5m) to EBITDA (257.5m) ratio: -0.95 <= 3.0 (WARN <= 3.5)

Current Ratio 1.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (61.6m) change vs 12m ago -2.48% (target <= -2.0% for YES)

Gross Margin 85.39% (prev 85.58%; Δ -0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 35.22% (prev 32.58%; Δ 2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.13 (EBITDA TTM 257.5m / Interest Expense TTM 200.9m) >= 6 (WARN >= 3)

Altman Z'' 0.72

(A) 0.13 = (Total Current Assets 3.76b - Total Current Liabilities 2.27b) / Total Assets 11.36b

(B) 0.04 = Retained Earnings (Balance) 442.7m / Total Assets 11.36b

(D) -0.02 = Book Value of Equity -127.2m / Total Liabilities 7.40b

Total Rating: 0.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 57.44

1. Piotroski 6.0pt = 1.0

2. FCF Yield 17.30% = 5.0

3. FCF Margin 32.14% = 7.50

4. Debt/Equity 0.27 = 2.46

5. Debt/Ebitda -0.95 = 2.50

6. ROIC - WACC (= -11.89)% = -12.50

7. RoE -9.25% = -1.54

8. Rev. Trend 55.97% = 4.20

9. EPS Trend -23.57% = -1.18

What is the price of JAZZ shares?

As of November 14, 2025, the stock is trading at USD 141.71 with a total of 859,100 shares traded.
Over the past week, the price has changed by +5.71%, over one month by +4.86%, over three months by +21.00% and over the past year by +11.01%.

Is Jazz Pharmaceuticals a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Jazz Pharmaceuticals is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 57.44 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JAZZ is around 140.67 USD . This means that JAZZ is currently overvalued and has a potential downside of -0.73%.

Is JAZZ a buy, sell or hold?

Jazz Pharmaceuticals has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy JAZZ.

Strong Buy: 10
Buy: 6
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the JAZZ price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	188.9	33.3%
Analysts Target Price	188.9	33.3%
ValueRay Target Price	153.9	8.6%

JAZZ Fundamental Data Overview November 10, 2025

Market Cap USD = 7.97b (7.97b USD * 1.0 USD.USD)
P/E Forward = 6.8966
P/S = 1.9169
P/B = 2.2456
P/EG = 6.0482
Beta = 0.332
Revenue TTM = 4.16b USD
EBIT TTM = -428.0m USD
EBITDA TTM = 257.5m USD
Long Term Debt = 6.08b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.03b USD (from shortTermDebt, last quarter)
Debt = 1.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -243.5m USD (from netDebt column, last quarter)
Enterprise Value = 7.73b USD (7.97b + Debt 1.08b - CCE 1.33b)
Interest Coverage Ratio = -2.13 (Ebit TTM -428.0m / Interest Expense TTM 200.9m)
FCF Yield = 17.30% (FCF TTM 1.34b / Enterprise Value 7.73b)
FCF Margin = 32.14% (FCF TTM 1.34b / Revenue TTM 4.16b)
Net Margin = -8.86% (Net Income TTM -368.5m / Revenue TTM 4.16b)
Gross Margin = 85.39% ((Revenue TTM 4.16b - Cost of Revenue TTM 607.4m) / Revenue TTM)
Gross Margin QoQ = 77.11% (prev 88.88%)
Tobins Q-Ratio = 0.68 (Enterprise Value 7.73b / Total Assets 11.36b)
Interest Expense / Debt = 4.49% (Interest Expense 48.6m / Debt 1.08b)
Taxrate = -2683 % (out of range, set to none) (-242.4m / 9.04m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.65 (Total Current Assets 3.76b / Total Current Liabilities 2.27b)
Debt / Equity = 0.27 (Debt 1.08b / totalStockholderEquity, last quarter 3.96b)
Debt / EBITDA = -0.95 (Net Debt -243.5m / EBITDA 257.5m)
Debt / FCF = -0.18 (Net Debt -243.5m / FCF TTM 1.34b)
Total Stockholder Equity = 3.98b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.24% (Net Income -368.5m / Total Assets 11.36b)
RoE = -9.25% (Net Income TTM -368.5m / Total Stockholder Equity 3.98b)
RoCE = -4.25% (EBIT -428.0m / Capital Employed (Equity 3.98b + L.T.Debt 6.08b))
RoIC = -5.52% (negative operating profit) (EBIT -428.0m / (Assets 11.36b - Curr.Liab 2.27b - Cash 1.33b))
WACC = 6.37% (E(7.97b)/V(9.05b) * Re(7.24%) + (debt cost/tax rate unavailable))
Discount Rate = 7.24% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -5.97%
[DCF Debug] Terminal Value 81.07% ; FCFE base≈1.25b ; Y1≈1.51b ; Y5≈2.42b
Fair Price DCF = 681.0 (DCF Value 41.38b / Shares Outstanding 60.8m; 5y FCF grow 21.58% → 3.0% )
EPS Correlation: -23.57 | EPS CAGR: 27.38% | SUE: 0.91 | # QB: 1
Revenue Correlation: 55.97 | Revenue CAGR: 5.49% | SUE: 0.49 | # QB: 0

Additional Sources for JAZZ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle